Literature DB >> 14982964

Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension.

Erica A Wehrwein1, Carrie A Northcott, Robert D Loberg, Stephanie W Watts.   

Abstract

Hypertension is characterized by abnormal vascular contractility and function. Arteries from deoxycorticosterone acetate (DOCA)-salt hypertensive rats develop spontaneous tone that is not observed in arteries from normotensive rats. Inhibition of phosphoinositide 3-kinase (PI3-kinase) by 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) reduces spontaneous tone development. The Rho/Rho-kinase pathway has been suggested to play a role in hypertension and may be dependent on PI3-kinase activity. We hypothesized that Rhokinase is involved in spontaneous tone development and that Rho/Rho-kinase is a downstream effector of PI3-kinase. Using endothelium-denuded aortic strips in isolated tissue bath, we demonstrated that (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) (Y27632) (1 microM), a Rho-kinase inhibitor, significantly reduced spontaneous tone in the DOCA aorta but that it did not affect sham aorta basal tone (DOCA 63.5 +/- 15.9 versus sham 1.2 +/- 0.4 total change in percentage of phenylephrine contraction). We examined the interaction between the PI3-kinase and Rho pathways by observing the effects of LY294002 on a Rhokinase effector, myosin phosphatase (MYPT), and Y27632 on a PI3-kinase effector, Akt, using Western blot analysis. Inhibition of PI3-kinase reduced spontaneous tone, but it had no effect on the phosphorylation status of MYPT, indicating that PI3-kinase is not a downstream effector of Rho/Rho-kinase. These data indicate that there is little interaction between the Rho/Rhokinase and PI3-kinase pathways in the DOCA-salt aorta, and the two pathways seem to operate in parallel in supporting spontaneous arterial tone. These data reflect spontaneous tone only and do not rule out the possibility of interaction between these pathways in agonist-stimulated tone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982964     DOI: 10.1124/jpet.103.062265

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats.

Authors:  Takayuki Matsumoto; Rita C Tostes; R Clinton Webb
Journal:  Pharmacol Res       Date:  2011-09-14       Impact factor: 7.658

Review 2.  The role of Rho protein signaling in hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Nat Rev Cardiol       Date:  2010-08-31       Impact factor: 32.419

3.  Angiotensin II utilizes Janus kinase 2 in hypertension, but not in the physiological control of blood pressure, during low-salt intake.

Authors:  Amy K L Banes-Berceli; Hind Al-Azawi; Daniel Proctor; Harvey Qu; Dominic Femminineo; Crystal Hill-Pyror; R Clinton Webb; Michael W Brands
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-03       Impact factor: 3.619

4.  Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism.

Authors:  Takeshi Matsumoto; Kenji Oki; Masato Kajikawa; Ayumu Nakashima; Tatsuya Maruhashi; Yumiko Iwamoto; Akimichi Iwamoto; Nozomu Oda; Takayuki Hidaka; Yasuki Kihara; Nobuoki Kohno; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Hypertension       Date:  2015-01-26       Impact factor: 10.190

5.  Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study.

Authors:  Shinji Kishimoto; Kenji Oki; Tatsuya Maruhashi; Masato Kajikawa; Shogo Matsui; Haruki Hashimoto; Yuji Takaeko; Yasuki Kihara; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Farina Mohamad Yusoff; Ayumu Nakashima; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  J Hypertens       Date:  2019-05       Impact factor: 4.844

Review 6.  Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: An update.

Authors:  Zhichao Zhou; Takayuki Matsumoto; Vera Jankowski; John Pernow; S Jamal Mustafa; Dirk J Duncker; Daphne Merkus
Journal:  Pharmacol Res       Date:  2018-12-13       Impact factor: 7.658

7.  Uridine adenosine tetraphosphate-induced contraction is increased in renal but not pulmonary arteries from DOCA-salt hypertensive rats.

Authors:  Takayuki Matsumoto; Rita C Tostes; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-06       Impact factor: 4.733

8.  Pyk2 mediates increased adrenergic contractile responses in arteries from DOCA-salt mice - VASOACTIVE PEPTIDE SYMPOSIUM.

Authors:  Fernanda R C Giachini; Fernando S Carneiro; Victor V Lima; Zidonia N Carneiro; Maria Helena C Carvalho; Zuleica B Fortes; R Clinton Webb; Rita C Tostes
Journal:  J Am Soc Hypertens       Date:  2008 Nov-Dec

9.  Mechanisms of augmented vasoconstriction induced by 5-hydroxytryptamine in aortic rings from spontaneously hypertensive rats.

Authors:  K Budzyn; R M Ravi; A A Miller; C G Sobey
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

Review 10.  Redox signaling, vascular function, and hypertension.

Authors:  Moo Yeol Lee; Kathy K Griendling
Journal:  Antioxid Redox Signal       Date:  2008-06       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.